| __timestamp | CRISPR Therapeutics AG | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 9335772 |
| Thursday, January 1, 2015 | 12573000 | 999000 |
| Friday, January 1, 2016 | 42238000 | 978000 |
| Sunday, January 1, 2017 | 69800000 | 952000 |
| Monday, January 1, 2018 | 113773000 | 956000 |
| Tuesday, January 1, 2019 | 179362000 | 8122999 |
| Wednesday, January 1, 2020 | 269407000 | 8712000 |
| Friday, January 1, 2021 | 17953000 | 13980000 |
| Saturday, January 1, 2022 | 110250000 | 21135000 |
| Sunday, January 1, 2023 | 130250000 | 10755000 |
| Monday, January 1, 2024 | -2314000 |
Infusing magic into the data realm
In the dynamic world of biotechnology, understanding financial health is crucial. This analysis delves into the cost of revenue trends for CRISPR Therapeutics AG and Iovance Biotherapeutics, Inc. over the past decade. CRISPR Therapeutics, a pioneer in gene editing, saw its cost of revenue skyrocket by over 8,500% from 2014 to 2023, reflecting its aggressive expansion and scaling efforts. In contrast, Iovance Biotherapeutics, specializing in cancer immunotherapy, experienced a more modest increase of around 15% during the same period, indicating a steady but cautious growth strategy.
The year 2020 marked a peak for CRISPR with costs reaching their zenith, while Iovance's costs remained relatively stable. This divergence highlights the contrasting business models and market strategies of these two biotech giants. As the industry evolves, these insights offer a glimpse into the financial strategies shaping the future of biotechnology.
Cost of Revenue Comparison: Pfizer Inc. vs CRISPR Therapeutics AG
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and CRISPR Therapeutics AG's Expenses
Cost of Revenue Comparison: Grifols, S.A. vs CRISPR Therapeutics AG
Cost of Revenue Trends: Telix Pharmaceuticals Limited vs Iovance Biotherapeutics, Inc.
Cost Insights: Breaking Down Ionis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: CRISPR Therapeutics AG vs Ligand Pharmaceuticals Incorporated
CRISPR Therapeutics AG vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: CRISPR Therapeutics AG vs Wave Life Sciences Ltd.
Analyzing Cost of Revenue: CRISPR Therapeutics AG and Celldex Therapeutics, Inc.
Cost Insights: Breaking Down CRISPR Therapeutics AG and Viridian Therapeutics, Inc.'s Expenses
Cost of Revenue Trends: Bausch Health Companies Inc. vs Iovance Biotherapeutics, Inc.
Comparing Cost of Revenue Efficiency: Iovance Biotherapeutics, Inc. vs Travere Therapeutics, Inc.